CD19 and neoplasm: To determine whether multiple infusions of the cells could further enhance the antitumor activity, tumor‐bearing NOG mice were administered with vehicle, cryopreserved CD19‐CAR‐DNTs either once or thrice intravenously (on Days 1, 8 and 15).